Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: An updated systematic review and meta-analysis

Expert Review of Anticancer Therapy

Volumn 14, Issue 6, 2014, Pages 751-760

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

alopecia; hand foot skin reaction; meta analysis; mucocutaneous toxicities; skin rash; sorafenib; stomatitis or pruritus

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR PROTEIN;

ADVERSE DRUG REACTION; ALOPECIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SKIN REACTION; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; MONOTHERAPY; MUCOCUTANEOUS TOXICITY; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; SOLID TUMOR; STOMATITIS; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; ENZYMOLOGY; HAND-FOOT SYNDROME; MUCOSITIS; NEOPLASMS; RISK;

ALOPECIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ERUPTIONS; HAND-FOOT SYNDROME; HUMANS; INCIDENCE; MUCOSITIS; NEOPLASM PROTEINS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PRURITUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES; RISK;

EID: 84901393568     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.894465     Document Type: Review

References (33)

1. Cascinu S, Berardi R, Sobrero A, et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreaticcancer: A GISCAD randomized phase II study. Dig Liver Dis 2014;46(2):182-6
2. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): From bench to bedside. J Egypt Natl Canc Inst 2013;25(4):165-71
3. Marampon F, Gravina GL, Popov VM, et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol 2014;44(1):285-94
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1):25-34
5. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552-62
6. Abdel-Rahman O. Exploring systemic options for advanced hepatocellular carcinoma. (1st edition). LAP LAMBERT Academic publishing, Saarbrücken, Germany; ISBN-13: 978-3-659-43013-8 2013
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4): 378-90
8. Abdel-Rahman O, Elsayed Z. Combination transarterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: A systematic review of the literature. Dig Dis Sci 2013;58(12):3389-96
9. Bayer pharma, nexavar prescribing information. Available from:Www. univgraph. com/bayer/inserts/nexavar. pdf
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62(10):1006-12
11. National cancer institute, common toxicity criteria. Available from: Http://ctep. cancer. gov/protocoldevelopment/ electronic-applications/docs/ ctcaev3. pdf
12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3): 177-88
14. Yoshiji H, Kuriyama S, Yoshii J, et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004;39:1517-24
15. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egyptian Nat Cancer Inst 2014 Mar; 26(1):9-13
16. Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma; Med Oncol. 2013;30(3):655
17. Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma; a systematic review of the literature. Crit Rev Oncol Hematol. Available from: Http://dx. doi. org/10. 1016/j. critrevonc. 2013. 12. 013
18. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-24
19. Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47(2):176-86
20. Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013;130(1): 25-30
21. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47(14):2117-27
22. Gradishar WJ, Kaklamani V, Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013;49(2):312-22
23. Gonçalves A, Gilabert M, François E, et al. BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23(11):2799-805
24. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2): 125-34
25. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
26. Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(18): 2582-9
27. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30(25):3084-92
28. Baselga J, Segalla JG, Roché H, et al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; 30(13):1484-91
29. Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012;18(4):1129-37
30. El-Khoueiry AB, Ramanathan RK, Yang DY, et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs 2012;30(3): 1175-83
31. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study. Ann Oncol 2011;22(7):1528-34
32. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 2010;304(19):2154-60
33. Procopio G, Verzoni E, Bracarda S, et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): Final results of the ROSORC trial. Ann Oncol 2013;24(12):2967-71